Emerging Distortion Product Otoacoustic Emission Techniques to Identify Preclinical Warning Signs of Basal Cochlear Dysfunction Due to Ototoxicity
Year: 2019
Type: article
Abstract: Hundreds of medications commonly prescribed for anticancer treatments and some infections are known to cause hearing damage, referred to as ototoxicity. Preventing or minimizing ototoxicity is critical in order to preserve quality of life for patients receiving treatment and to reduce the societal burden of hearing loss. Current clinical evaluations are restricted to a limited frequency range (≤8 kHz); however, this approach does not permit the earliest detection of ototoxicity, most likely to be observed at the highest frequencies (9–20 kHz). Distortion product otoacoustic emissions (DPOAEs) offer a noninvasive, objective approach to monitor cochlear health in those unable to respond via conventional methods. The current report analyzes different DPOAE paradigms used in patients undergoing chemotherapy treatments with various platinum derivatives. Individualized serial monitoring protocols were completed at the highest frequencies with measurable DPOAEs. This allowed the exploration of potential clinical translation opportunities for further quantification of the earliest signs of underlying cochlear damage, which may go undetected with conventional methods. Clinical practice has the potential to be enhanced by emerging DPOAE applications, including targeted monitoring protocols and high-frequency stimuli to assess cochlear function, especially at the highest frequencies, and advanced calibration techniques to ensure the stability of serial measurements.
Source: Applied Sciences
DOI: 10.3390/app9153132
Institutions: Mayo Clinic, San Diego State University
Language: English
Subfield: Sensory Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,520
OpenAlex ID: W2965950037